crew

In the U.S., the inventor has a "first to invent" claim which is different from other patenting organizations throughout the world who generally utilize "first to file." Debate over this issue, and which model best influences economic development is ongoing. Some are concerned that a change in patent rights may harm the small startup and benefit the incumbents with deeper pockets. You can read more about this topic.

Proper organization of a patent porfolio is essential to be prepared to properly navigate the IP landscape. One key issue is related to inventorship. Consider the Pfizer patent, patent # 5,760,06^, which is commonly known as the COX-2 inhibitor. Pfizer is currently in a $1B lawsuit because Searle, the original owner of the patent, failed to include a key inventor on the patent. Pfizer inherited this mess when they acquired Pharmacia, who had previously acquired Monsanto, who had previously acquired Searle. Ignorance is not a defensible excuse in patent litigation.

During development, IP Street was very fortunate and grateful to have early partners that signed on to use our tools, often in beta form. Through timely and constructive feedback, our partners were instrumental in helping us develop features that evolved from "interesting and cool" to "nice to have" to "got to have". Below is a sampling of some of the enterprise partners who understood our vision very early on. They became annual subscribers and were afforded the benefits of having direct access to our development team, enabling us to design more relevant tools and allowing them to enjoy influence in design priorities. They include: Alibaba, Amazon, Lee & Hayes, PAML, T-Mobile. Thank you to all of our enterprise partners.